TRESIBA Kahiki > Insulin

Nā hōʻailona no ka hoʻohana ʻana
Ke ʻano o ka noi
Nā hopena hopena
Nā Hoʻohui
Kahawai
Hoʻopili pū me nā lāʻau ʻē aʻe
Ke keu
Nā kūlana mālama
E hoʻokuʻu i ke ʻano
Hōʻike

Ka lāʻau Keliki Tresiba - He mea hoʻohālikelike o ka insulin o ke kanaka o ka lōʻihi lōʻihi, i hoʻolālā ʻia e ka lāʻau o ka mea i hana ai i ka biotechnology DNA e hoʻohana ana i ke kumu Sacharomyces cerevisiae.
Hoʻopili kūloheloheʻo Insulin degludec i ka mea nāna i hopu i ka insulin endogenous a me ka hoʻopili pū ʻana me ia, ʻike pū i kona ʻano lapaʻau e like me ka hopena o ka insulin kanaka.
ʻO ka hopena hypoglycemic hopena o ka insulin degludec ma muli o ka hoʻonui nui o ka hoʻohana ʻana i ka glucose ma o ke kino ma hope o ka hoʻopaʻa ʻana i ka insulin i ka ʻāʻī a me nā mea hoʻonaʻauao sela a me ka hoʻokaʻawale ʻana i ka hopena o ka hana glucose i ka ate.
Ka lāʻau Keliki Tresiba ʻO kahi analogal basal o ka insulin kanaka o ka hana superlong, ma hope o ke kaupaʻi sc, he puka ia i ka hopena o ka multihexamers i ka depot subcutaneous, mai laila ka hoʻomau mau ʻana a me ka lōʻihi o ka hoʻokaʻawale ʻana o ka insulin degludec i loko o ke kahe, e hoʻolako nei i kahi pālahalaha loa o ka hana a ka hopena hypoglycemic paʻa o ka lāʻau lapaʻau. I ka manawa o ka mālama ʻana i 24 mau hola o ka hopena hypoglycemic o ka lāʻau i nā mea maʻi no ka hoʻolaʻa ʻia o ka nui o ka insulin degludec 1 manawa / lā, ka hoʻomākaukau ʻana ʻo Tresiba FlexTouch, ʻokoʻa ʻole i ka glargine insulin, i hōʻike mai i kahi Vd like ma waena o nā hana i ka wā mua a me ka ʻelua mau hola 12.
ʻO ka lōʻihi o ka hana o ka lāʻau Tresiba FlexTouch ʻoi aku ma mua o nā hola 42 i loko o ka hopena o ka hopena therapeutic. Css o ka lāʻau i loko o ke koko koko ua loaʻa i nā lā 2-3 ma hope o ka hoʻomakeʻa ʻana o ka lāʻau lapaʻau.

E hoʻokuʻu i ke ʻano, ka pūpū a me ka hoʻonohonoho

ʻO ke kūleʻa no ka hoʻokele sc, he ʻulaʻula ʻole.

1 ml
insulin degludec	100 PIECES * (3.66 mg)

Nā mea kūʻai: glycerol - 19.6 mg, phenol - 1,5 mg, metacresol - 1,72 mg, zinc - 32,7 μg (ma ke ʻano o ka zinc acetate - 109.7 μg), ka waikila hydrochloric / sodium hydroxide (no ka hoʻoponopono pH), ka wai d / a - hiki i ka 1 ml.

3 ml (300 PIECES) - nā pahu pahu aniani (1) - hoʻopau i nā penikala syringe he nui no nā inikini (5) - nā ʻeke pepa.

* 1 UNIT he 36,6 μg o ka aniani me ka paʻakai paʻakai ole, ka mea e pili ana me 1 IU o ke kino kanaka, 1 UNIT o ka insulin detemir a i nā mea hoʻonani insulin.
i ka pH o ka hoʻonā he 7.6.

Ka hana lāʻau lapaʻau

ʻO ka insulin manuahi lōʻihi lōʻihi e loaʻa i ka DNA biominola recombinant me ka hoʻohana ʻana i ka mana Saccharomyces cerevisiae. ʻO kahi mea hoʻohālikelike ia o ka insulin kanaka.

Hoʻopili kūloheloheʻo Insulin degludec i ka mea nāna i hopu i ka insulin endogenous a me ka hoʻopili pū ʻana me ia, ʻike pū i kona ʻano lapaʻau e like me ka hopena o ka insulin kanaka.

ʻO ka hopena hypoglycemic hopena o ka insulin degludec ma muli o ka hoʻonui nui o ka hoʻohana ʻana i ka glucose ma o ke kino ma hope o ka hoʻopaʻa ʻana i ka insulin i ka ʻāʻī a me nā mea hoʻonaʻauao sela a me ka hoʻokaʻawale ʻana i ka hopena o ka hana glucose i ka ʻāʻī.

Lapaʻau lāʻau

ʻO ka hana superlong o ka insulin degludec ma muli o ke ʻano hana kūikawā o kāna molekue. Ma hope o ka hoʻonāukiuki subcutaneous, kūkulu ʻia nā multihexamers stabil e kāpae i ka depot insulin i loko o ka kiko adipose subcutaneous. Hoʻololi ka multihexamers e hoʻokuʻu nei i ka hoʻololi, a hoʻokuʻu i ka degludec insulin monomers, e hoʻopiʻi ana i ka hoʻokuʻu a hoʻolōʻihi i ka lāʻau i loko o ke koko. Loaʻa nā c ss i nā kahe koko koko i nā lā 2-3 ma hope o ka hoʻokō ʻana. ʻO ka hana o ka insulin degludec no 24 mau hola me kāna alakaʻi o kēlā me kēia lā 1 mau lā / lā a ka manawaleʻa ʻia ma waena o 12 a me 12 mau hola o ka hola (AUC GiR, 0-12h, SS / AUC GiR, t, SS = 0.5). ʻO ka mea paʻa o ka insulin degludec i nā protein plasma (albumin) he> 99%. Hoʻohālikelike ka hoʻonāukiuki ʻana o ka insulin degludec me ka like o ka insanne kanaka, ʻaʻole ikaika nā metabolites a pau. T 1/2 ma hope o ka inake o ka scection he 25 mau hola a ʻaʻole ia he hilinaʻi. Me ka hoʻokele sc, ua hoʻohālikelike ka nui o nā kukuna plasma i ka hopena e lawelawe ʻia ana ma ka nui o nā pōkole therapeutic.

Hōʻikeʻike i nā lāʻau lapaʻau

Hoʻopiʻi i nā pākeke.

Nā helu ICD-10

ʻIke ICD-10	Hōʻike ʻano
E10	ʻAno maʻi type 1
E10.0	ʻO ka diabetes mellitus e hilinaʻi ʻia me ka coma
E10.5	Insulin-hilinaʻi mellitus maʻi mika me ka maʻi peripheral maʻi (a me ke ulcer, gangrene)
E11	ʻAno maʻi type 2
E11.5	Non-insulin-hilinaʻi mellitus mellitus me peripheral circulation disorders (me ka ulcer, gangrene)

Loaʻa ka hopena

Ma ka ʻāpana o ka ʻōnaehana pale: līkī - i ke ʻano o ka hypersensitivity, urticaria.

Mai ka ʻaoʻao o ka metabolism a me kaʻaiʻai: pinepine pinepine - hypoglycemia.

Mai ka ʻili a me nā ʻili subcutaneous: pinepine - lipodystrophy.

ʻO nā hopena maʻamau: pinepine - peripheral edema.

Nā kūmole kūloko: pinepine -, ʻeha, ka hemorrhage kūloko, erythema, nodular hoʻohui konupili, ka nui, ke kīleʻamaʻa ʻana o ka ʻili, ka ʻūʻī, ka huhū a me ka paʻa ʻana ma ka wahi i ʻōlelo ʻia. ʻO ka hapanui o nā pane ma ka pūnaewele ʻoi aku ka liʻiliʻi a lūlū a neʻe me ka mālama mau ʻia ʻana.

ʻŌpū a me ka lactation

Contraindicated ke kahunapule. ʻAʻole i hōʻike ʻia nā haʻawina o ka hana hoʻohālikelike holoholona i nā ʻokoʻa ma waena o ka insulin degludec a me ka insulin kanaka i ka ʻōlelo o ka embryotoxicity a me ka teratogenicity.

Hoʻohana ma ka wā o ka umauma i contraindicated, ʻoiai ʻaʻoheʻike pilikino i ka hānai wahine. Ua hōʻike ʻia nā haʻawina holoholona i nā nāu, hoʻēʻe ʻia ka insulin melepecec i loko o ka waiū umauma, a ʻo ka ʻaihue ʻana o ka lāʻau i ka waiū umauma ua haʻahaʻa ma lalo o ke koko koko. ʻAʻole ʻike ʻia inā ua excreted i ka insulin manu kanaka i ka waiū kanaka.

Nā ʻōlelo kikoʻī

ʻO ka hoʻoneʻe ʻana o ka mea maʻi i kahi ʻano hou a hoʻomākaukau paha no ka insulin i kahi hōʻailona hou a i ʻole e hana ʻia kekahi mea hana ma lalo o ka mākaʻi loea koʻikoʻi. I ka unuhi ʻana, pono ia ka hoʻoponopono hoʻoponopono ʻia.

Ua hōʻike ʻia nā pilikia o ka hoʻomohala ʻana i ka puʻuwai naʻau i ka mālama ʻana i nā mea maʻi me ka thiazolidinediones i hui pū me ka hoʻomākaukau ʻana i ka insulin, ʻoiai inā he mau pilikia ko ia mau maʻi no ka hoʻomohala ʻana o ka naʻau puʻuwai. I ka koho ʻana i kēlā ʻano hui, pono pono e hana i nā hoʻokolohua olakino e pili ana i nā maʻi e hoʻomaopopo i nā hōʻailona a me nā hōʻailona o ka puʻuwai puʻuwai kino, loaʻa ʻana o ke kaumaha, a me ka edema peripheral. Inā hele i nā hopena o ka puʻuwai naʻau i loko o nā mea maʻi, pono e hoʻokaʻawale ke ʻano me ka thiazolidinediones.

Ka hoʻonāukiuki ʻana o ka inikini insulin me ka hoʻomaikaʻi koʻikoʻi i ka kaohi o ka mea laʻala kalaiwa hiki ke alakaʻi i kahi wā pōkole i ke kūlana o ka maʻi retinopathy maʻi, ʻoiai ka lōʻihi o ka hoʻomaikaʻi ʻana i ka glycemic control hōʻemi i ka hopena o ka holomua o ka maʻi retinopathy diabetes.

Ke hoʻohana nei i ka insulin, ua hiki ke kanu ʻia o ka antibody. I nā hihia liʻiliʻi, koi aku ka wae ʻana i ka antibody i ka hoʻoponopono ʻana o ka insulin e pale i nā hihia o ka hyperglycemia a i ʻole hypoglycemia.

Hoʻopilikia i ka hiki ke hoʻokau i nā kaʻa a me nā māka

Hiki i ka poʻe maʻi ke nānā i ka wikiwiki a me ka wikiwiki o ka hopena i ka wā o ka hypoglycemia, hiki ke hōʻeha i nā kūlana i mea e pono ai kēia mana (no ka laʻana ke kime ʻana i nā kaʻa a i nā mīkini paha). Pono e ʻōlelo ʻia nā mea maʻi e hana i nā hana e pale ai i ka hoʻomohala ʻana o ka hypoglycemia i ka wā e holo ana. He mea koʻikoʻi loa kēia no nā poʻe maʻi me ka ʻole a hōʻemi iki paha i nā hōʻailona o nā mea hana mua i ka hoʻomohala ʻana i ka hypoglycemia a i ʻole mau manawa pinepine o ka hypoglycemia. I kēia mau hihia, pono ke noʻonoʻo ʻia ka kūpono o ka hoʻokele kaʻa.

Hoʻohui nūhou

ʻO ka pono o ka insulin e hiki ke hoʻemi ʻia: nā lāʻau lapaʻau hypoglycemic waha, like me ka ponaida-like peptide-1 agonists receptor (GLP-1), paleO MAO, beta-blockers non-selective, inhibitions ACE, salicylates, anabolic steroid and sulfonamides.

Hiki i ka insulin ke hoʻonui i ka: oral contraceptives oral, thiazide diuretics, corticosteroids, thyroid hormone, sympathomimetics, somatropin a me danazole.

Hiki i nā beta-blockers ke uhi i nā hōʻailona o ka hypoglycemia.

Hiki i ka Octreotide / lanreotide ke hoʻonui a hoʻopau i ka pono o ke kino no ka insulin.

Hiki i ka Ethanol (waiʻona) ke hoʻoikaika a hōʻemi i ka hopena hypoglycemic o ka insulin.

Nā hiʻohiʻona

ʻO kēia kahi hoʻomākaukau hana lōʻihi o ka hana i hana ʻia e NovoNordisk. ʻO ka lāʻau lapaʻau ma kāna mau ʻano e ʻoi aku ma o Levemir, Tujeo a me nā mea ʻē aʻe. ʻO ka lōʻihi o ka hoʻonā ʻana i nā hola 42.

ʻO kahi hōʻailona maʻamau o ka overdose ka hypoglycemia. Hoʻomohala ke ʻano ma muli o kahi hoʻemi o ka nui o ka glucose i ke kino kū'ē i ke kua o kahi nui o ka hōʻuluʻulu ʻana o ka insulin. Hōʻike ʻia ka hypoglycemia e nā hōʻailona he nui, ma muli o ka paʻakikī o ke kūlana o ka mea maʻi.

Kākau mākou i nā hōʻailona nui:

hilo
makewai
pololi
ka malo maloʻo
hoʻokaʻawale ʻaʻa
nahoa
nā lima haʻalulu
lagona ka manaʻo
hopohopo
pilikia ana i ka hana pono a me ka ʻike,
coma a ao ʻole paha o ka noʻonoʻo.

ʻO ke kōkua mua no ka hypoglycemia pumehana he poʻe kokoke, hiki i ka mea maʻi ke kōkua i kekahi manawa iā lākou iho. No kēia, maʻamau ke ʻano o ka glucose i ke koko. E kū'ē i ke kua o nā hōʻailona o ka hyperglycemia, hiki iā ʻoe ke hoʻohana i kahi mea momona, nā meaʻai a pau e loaʻa ai nā calcium. Hoʻohana pinepine ʻia ka ʻaila kō i loko o ia mau ʻano.

Ke kapa ʻia kahi kauka inā he pau ka mea maʻi. Me ka hoʻolālā ikaika o ka hypoglycemia, hiki ke lawelawe ʻia ka glucagon ma ka nui o 0.5-1 mg. Inā ʻaʻole hiki i kēia lāʻau lapaʻau, hiki ke hoʻohana ʻia nā ʻano antagonist like ʻole.

Hiki iā ʻoe ke hoʻohana i nā unuhi me nā hormones, catecholamines, adrenaline, i loko o ka hale hoʻomaha, ua maʻi ʻia ka mea maʻi me ka glucose intravenously, ke nānā nei lākou i ka pae o ke kō i loko o ke koko i ka wā o ka hana a ka dropper. Hoʻopili ʻia, ka nānāʻana o nā electrolytes a me ka hoʻolika wai-paʻakai.

ʻO ka hui a me ke ʻano o ka lāʻau lapaʻau

Loaʻa ka lāʻau lapaʻau ʻo Tresiba Flextach i ke ʻano o ka peni syringe me kahi pahu e hoʻopili pū ʻia ai. Loaʻa ka lāʻau lapaʻau i 2 mau dosages, kahi maʻalahi loa no nā mea maʻi me ke kaumaha nui o ke kino a me kahi papa paʻakikī o ka maʻi maʻi. Ma kēlā me kēia pahu pahu. Wahi a ia, he ʻumi nā papa a 300 a he 600 mau ʻāpana o ka insulin.

I ka 1 ml o ka hoʻonā ai no ka maʻi ʻaina, ʻo ka nui o ka insulin degludec 100 a me 200 mau unuhi.

Hoʻohui kekahi mau mea hoʻohui i ka lāʻau lapaʻau e hoʻomau i nā waiwai o ka insulin, hoʻomaikaʻi i ka hoʻoili ʻana a me ka bioavailability, me ka hoʻomoʻa ʻana o ka absorption a me ka excretion.

Loaʻa nā ʻano like:

Glycerol - 19.6 / 19.6 mg,
Metacresol - 1.72 / 1.72 mg,
Phenol - 1,5 / 1.5 mg,
ʻO ka waikila Hydrochloric,
Zinc - 32.7 / 71.9 mcg,
ʻO Sodium hydroxide,
Wai no ka hoʻonāukiuki - a hiki i ka 1/1 ml.

Hiki ke mālama ʻia ka lāʻau lapaʻau ma loko o kahi kaʻe o ka 80/160 U / kg. I kēia hihia, ʻo ka lae hoʻoponopono hoʻoponopono ʻāpana ka 1 a i ʻole 2 mau ʻāpana. Hoʻokahi like me kēlā me kēia kikowaena o ka degludec insulin i ka papa like o ka nui o ke insulin.

1 ml o ka hoʻonā i ka insulin degludec 100 UNITS (3.66 mg)

Nā hana hana i ka hana

Hoʻokumu ka hana o ka hana i ka lāʻau lapaʻau ma ka agonism piha o ka insulin degludec me ka endogenous kanaka. I ka wā hoʻowalewale ʻia, nakinaki ʻia ia i nā receptor insulin i loko o nā kiko, ʻoi loa ka io a me ka momona.

Hoʻokumu ʻia ka insulin degludec insulin e hoʻohana ana i ka ʻenehana genetic, e kōkua ana e hoʻokaʻawale i ka DNA o nā huakini o nā kaha o Saccharomyces cerevisiae. He like loa ko lākou ʻano genetic me ka insulin kanaka, nāna e hoʻomaʻamaʻa maikaʻi a hoʻomaikaʻi i ka hana o nā lāʻau lapaʻau. Pūnaewele ʻo Pork i hana ai. Akā ua hoʻoiho ʻo ia i nā ʻano he nui mai ka nui o ke ʻano o ka pilikia.

ʻO ka lōʻihi o kona hoʻolahaʻana i ke kino a me ka mālama o nā pae insulin basal no 24 mau manawa e hoʻonāukiuki ʻia e kona mau hiʻohiʻona pilikino o ka hoʻopili ʻana mai ka momona subcutaneous.

I ka wā e lawelawe ai i ka subcutaneously, hana i ka insulin degludec i kahi hoʻomana o ka multihexamers soluble. Hoʻopili ikaika nā molecules i nā ʻāpana momona, kahi e hōʻoia ai i ka hoʻoluhi wikiwiki ʻana a me ka hoʻonui ʻana i ka lāʻau i loko o ke kahe koko.

Nā ʻōkuhi no ka hoʻohana

Hoʻokomo ka maʻi maʻi maʻi iā ia iho i ka lā. Hoʻoholo ʻia ka dosage e ke kauka e ka endocrinologist ma hope o ke ʻano ʻana i nā hoʻokolohua, e hoʻomaopopo ana i nā pono o ke kino o ka mea maʻi.

Ma nā hana mua o ka papa o ka hana maʻi, kahi maʻi o nā ʻāpana he 10 a i ʻole 0.1-0.3 mau paona i pākeke. I ka wā e hiki mai ana, hiki iā ʻoe ke hoʻonui i ka hewa ma nā ʻāpana 1-2 i ka manawa. Hoʻohana ʻia ka lāʻau lapaʻau no monotherapy, i ka hui pū me nā hana ʻē aʻe o ka mālama ʻana i ka maʻi maʻi maʻi.

ʻO nā wahi no nā ʻōlelo hōʻemi:

Kuhi ʻia ka nui o 80 uniona i loko o ka mea maʻi i ka manawa.

Koho ʻia ka maʻi nui no kēlā me kēia maʻi e ka neʻe i ke kauka. Aia ka hānana i nā lula ma ke ala pono o ka maʻi, ke kaumaha o ka mea maʻi, ke ʻano hana, a me kahi ʻano kikoʻī e ʻimi ʻia e nā maʻi.

ʻO ka mike o ka hoʻokele manawa he 1 manawa i kēlā me kēia lā, ʻoiai ʻo Tresiba he insulin līlole me ka wikiwiki o ka hana. ʻO ka ʻōmapa mua i ʻōlelo ʻia he 10 PIECES a i ʻole 0.1 - 0.2 PIECES / kg. Eia hou, koho ʻia ka pākēneka e pili ana i nā unahi a me ke kūpaʻa ʻana o kēlā me kēia kanaka.

Hiki ke hoʻohana ʻia ka lāʻau lapaʻau e like me ka monotherapy, a me kahi mahele o ka mālama paʻakikī no ka mālama maʻamau i ka pae mau o ka insulin. E hoʻohana mau i ka manawa like o ka lā e pale ai i ka hoʻomohala ʻana o ka hypoglycemia.

Hoʻolima wale ʻia ka insulin lōʻihi e hana ai ʻo Levemir i ka subcutaneously wale nō, e like me nā ala ʻē aʻe o nā ʻoihana e hiki ke hoʻopiʻi. ʻO nā wahi ʻoi loa ʻoi loa no ka injutaneous injection: nā ʻūhā, nā puʻuwai, nā poʻohiwi, nā pelepela deltoid a me ka paia ʻōpū.

Ma mua o kou hoʻomaka ʻana i ka hoʻohana ʻana i ka peni ʻoi, pono ʻoe e ʻike i nā lula no ka hoʻohana ʻana i kēia ʻōiwi. ʻ taughtlelo pinepine kēia e ke kauka kauka. A i ʻole e hele aku i ka mea maʻi i nā papa papa e hoʻomākaukau no ke ola me ka maʻi maʻi.

I loko o kēia mau papa, ke kamaʻilio nei lākou e pili ana i nā ʻāpana ʻai i nā meaʻai, nā loiloi kumu o ke ʻano e hilinaʻi nei ma ka mea maʻi, a me nā lula no ka hoʻohana ʻana i nā pā, peni a me nā mea hana ʻē aʻe no ka lawelawe ʻana i ka insulin.

Ma mua o ka hoʻomaka ʻana i ke kaʻina hana, pono ʻoe e hōʻoia i ka maopopo o ka peni ʻo syringe. I kēia hihia, pono ʻoe e hoʻolohe i ka pahu pahu, ka ʻoni o ka hoʻonā, ke ola a me ke lawelawe ʻana i nā valves. Eia ke ʻano o ka syringe-pen Tresib penei.

A laila hoʻomaka i ke kaʻina ponoʻī.

He mea kūpono ia e hoʻolohe pono i ka mea maʻamau e hoʻohana pono no ka hoʻohana kūʻokoʻa. Pono ka mea maʻi e ʻike pono i nā helu e hōʻike ʻia ana ma ka mea koho i ke koho ʻana i kahi maʻi. Inā ʻaʻole hiki ʻole kēia, pono ia e lawe i ka kōkua hou o kahi ʻē aʻe me kahi hihiʻo maʻamau.

E hoʻomākaukau koke i ka peni ʻo ka syringe no ka hoʻohana. No ka hana ʻana i kēia, pono mākou e wehe i ka pāpale mai ka penu ʻiwauka a me ke ʻano he maopopo i loko o ke kumu kīnā ʻana, ʻaʻole ʻonanekē i ka puka o ka pahu pahu. A laila e lawe i kahi pono huakaʻi a wehe i ka lepili mai ona. A laila hoʻomomi mālie i ka nira i ka paʻa a ʻoiai, me ke kuʻi.

Ma hope o ko mākou manaʻo paʻa ʻana e paʻa ka wili i ka peni syringe, e hoʻokaʻawale i ka pāpale waho a kau aku. Aia mau ʻia ka pāpale manawaleʻa kūloko o ka pahu o ka mea e pono ai ke hoʻokuʻu ʻia.

Mākaukau nā mea a pau no ka inikini, ʻike mākou i ka komo ʻana o ka insulin a me ke olakino o ka ʻōnaehana. No kēia, kau kahi kau o 2 mau pūʻulu i ka mea koho.e hāpai ke kāpili me ke kuikele a paʻa aʻe.

Ke kaomi nei i ka piston ma ke ala a pau, pono ke hōʻike i ka ʻelima. ʻO kēia ke kumu ua puka ka nui o ke ʻano. A ma ka hope o waho o ka pono wana e kū ʻia ai kahi hāʻule o ka pane. Inā ʻaʻole e hele kēia, e hoʻokau hou i nā hana e hōʻoia i ka ʻōnaehana e hana nei. Hāʻawi ʻia kēia 6 mau ho'āʻo.

Ma hope o ka kūleʻa ʻana o nā huki ʻana, hoʻomau mākou i ka hoʻomaka ʻana o ka lāʻau i loko o ka momona subcutaneous. No ka hana i kēia, e hoʻomaopopo pono i ka mea koho i kahi "0". A laila koho i ka pauma i makemake ʻia no ka hoʻokele ʻana.

A hoʻomanaʻo hoʻi hiki iā ʻoe ke komo i ka 80 a i ka 160 IU o ka insulin i ka manawa, kahi mea e hilinaʻi ai i ka nui o nā waihona i ka 1 ml o ka hoʻonā.

Hoʻokomo i kahi pū ma lalo o ka ʻili e hoʻohana ana i kekahi kaʻina a ke kauka i hōʻike ai ma ke aʻo ʻana. Hoʻopili i ka lāʻau pono i kēia kūlana. Ke kū ʻole nei i ka mea koho a ke neʻe ʻole nei ma ke ʻano, ke kaomi ʻana i ke pihi hoʻomaka i ke ala āpau.

A laila e kau i ka pāpale ma waho e pono ai ke huki aku ia mai ka paʻa ʻana, a laila haʻalele. Hoʻopili i ka peni syringe me kona pāpale ponoʻī.

ʻO nā hopena ʻino

Me kahi overdose, hele mai nā hypoglycemia, nā hōʻailona nui:

ua hāleʻa ka ʻili, palupalu ka naʻau,
ʻūlū, nalowale,
koma
pololi
piʻohū.

Hoʻopau ʻia ke ʻano maʻalahi me kā lākou iho, e hoʻohana ana i nā meaʻai i momona me nā calcium. Hana ʻia ke ʻano hoʻonaninani a me ka paʻakikī o ka hypoglycemia me nā inikini glucagon a i ʻole ka ʻano koi ʻana o ka dextrose, a laila ʻike ʻia nā mea maʻi, e hānai ʻia me nā meaʻai e loaʻa ana nā mea momona. Pono e hoʻokaʻaʻike i kahi loea no ka loli i ka dino.

No ka mālama ponoʻana i ka maʻi maʻi ma ka home, ʻōlelo ke akamai o nā loea

. ^ E Ha yM. He mea kupanaha kēia:

Hoʻolālā i nā glucose koko
Kāohi i ka hana pancreatic
E wehe i ka puffiness, ka hoʻoponopono i ka metabolism wai
Hoʻomaikaʻi i ka ʻike
He kūpono no nā pākeke a me nā keiki.
ʻAʻohe contraindications

Ua loaʻa i nā mea hana nā laikini pono e pono ai a me nā palapala hōʻoia ma Rusia a ma nā ʻāina e kokoke ana.

Hāʻawi mākou i kahi haʻawina i ka poʻe heluhelu o kā mākou pūnaewele!

Kūʻai ma ka pūnaewele mana

I ka wā mālama, hiki paha i nā hopena ʻino ke hopena. ʻO ka hopena maʻamau e hōʻike ai no ka hypoglycemia. Ua nānā ʻia, ma ke ʻano he lula ʻana, i kēlā mau maʻi i ʻoi aku ma mua o ke ʻano i hōʻike ʻia, pololei ʻole i ka hahai ʻana i nā ʻōkuhi, a i ʻole pololei ke koho ʻana i kēia mahele.

Hōʻike ʻia ka hypoglycemia e nā ʻano like ʻole, kahi i kēlā me kēia kekona a i ʻole ke hilinaʻi ʻana i ka lolo o ka lolo a me ke kōʻa koko. Hāʻawi ʻia ka hana koʻikoʻi e ka pae maʻamau o ke kō ka mea i hana ʻia ai ke kino o ka mea maʻi.

Hōʻike pinepine ʻia nā ʻōhumu Allergic. Hōʻike pinepine ʻia kēia hopena ma o ka hopena anaphylactic o kahi ʻano koke, e kū nei ma muli o ka hakakā kūloko o nā mea lapaʻau.

Hōʻike pinepine ʻia anaphylaxis ma ke ʻano o ka:

ʻĀlioiaʻi
ʻIwī
ʻO ka makeʻe o Quincke,
Erythema,
Anaphylactic pīhoihoi.

Hoʻomaopopo pinepine ʻia nā hopena kūloko i ka hoʻokele lāʻau. E hoʻopiʻi ka mea maʻi i ka ʻūlū ʻana o ka maʻi, kūloko, rashes ma ka wahi o ka injection. He ʻano maʻi a me nā ʻehaʻāina e kū nei i kahi ʻano.

ʻO ka maʻamau, nalowale nā hōʻailona ʻaoʻao ma hope o nā 2-3 mau pule o ka mālama mau. ʻO ia, ua loli nā hopena like ʻole i ke ʻano.

Hōʻike pinepine ʻia nā hiʻohiʻona o ka lipodystrophy i ka wā ʻaʻole i ukali ʻia nā ʻōlelo aʻoaʻo no ka hoʻohana ʻana. Inā ʻoe e ʻimi i nā lula a hoʻololi i ka pūnaewele injection i kēlā me kēia manawa, e emi ana ka hopena o ka hiki ʻana i nā lipodystrophy.

Ke keu

ʻO ka hōʻailona maʻamau o kahi overdose ka hypoglycemia. Ma muli o kēia ʻano ke emi ʻana o ka pae o ka glucose o ke koko ma kahi o ke kiʻekiʻe o ka piʻi ʻana o ka insulin. Hiki i ka hypoglycemia ke hōʻike iā ia iho me nā hōʻailona like ʻole, ka mea i hilinaʻi ʻia ma ka paʻakikī o ke kūlana.

Hiki ke kānalua ʻia ka hypoglycemia inā ʻike ʻia kekahi mau hōʻailona e like me kēia:

ʻʻAla
Kahuna
ʻIloli
Putu maloʻo
Kahuamo clammy kahe
Nā uhi momona
ʻIwī
Tremor
Palpitations
Ka manaʻo hopohopo
Mahele ʻōlelo a me ka hihiʻo,
Hoʻomaopopo pinepine ʻole i ka coma.

Hiki ke hāʻawi ʻia nā kōkua mua no ka hypoglycemia maʻalahi e nā ʻohana a i ʻole ka mea maʻi. No ka hoʻokaʻawale i ke ʻano, pono ʻoe e hoʻihoʻi i ke kaʻe o ka glucose koko i ke ʻano maʻamau.

E kū'ē i ke kua o nā hōʻailona o ka hypoglycemia, pono ʻoe e ʻai i kekahi mea momona, kekahi kīʻai i nā momona momona. Hiki i ke kōma ʻaila ke wikiwiki i ka home.

Inā ʻoi aku ka paʻakikī o ke ʻano a me ke kumu no ka lawehala ʻana, ʻaʻole ʻoe e kāhea koke i kahi ambulance. Me ka hypoglycemia koʻikoʻi, kuhikuhi e hōʻike i kahi hoʻohui antidote insulin - glucagon i loko o kahi pākaʻi o 0.5-1 mg intramuscularly a subcutaneously.

Inā nele ka glucagon no kekahi mau kumu, hiki ke hoʻololi ʻia e nā antagonist insulin ʻē aʻe. ʻO nā hormone thyroid, glucocorticoids, catecholamines, ma keʻano adrenaline, somatotropin hiki ke hoʻohana ʻia.

ʻO ka hana hou ke kau ʻia o kahi kaila intravenous o kahi hopena glucose a me ka hoʻomau mau ʻana i ke kō koko koko. Hoʻohui pono i nā electrolytes a me ka kaulike wai.

Nā kiʻi 3D

Hoʻopuka Kaiwai	1 ml
mea ikaika:
insulin degludec	100 PIECES (3.66 mg) / 200 PIECES (7.32 mg)
nā mea hoʻowalewale: glycerol, phenol, metacresol, zinc (as zinc acetate), hydrochloric acid / sodium hydroxide (no ka pH hoʻoponopono), ka wai no ka ʻōlelo
kūlea pH 7.6 / 7.6
1 peni mau peni he 3/3 ml o kahi ʻōnaehana e like me 300/600 UNITS. Hiki i ka syringe penia ke kiʻi iā ʻoe e komo i ka 80/160 PIECES i kahi maʻi i hoʻokomo ʻia ma ka hoʻonui ʻia ʻana o 1/2 PIECES
1 kuhi o ka insulin degludec i loaʻa i ka 0,0366 mg o ka anne hydrolyne i hoʻokaʻawale ʻia o ka melamine
1 IU o insulin degludec e kūlike ana i 1 IU o nā inanā no ke kanaka, 1 IU o ka insulin detemir a i ʻole insulin glargine

Nā kuleana a me nā kūlana e waiho ai

E mālama i ka peni insulin ma kahi o nā keiki. ʻO ka mahana mālama mālama pono ʻana i nā pahu kūmole i hoʻohana ʻole ʻia he 2-8 degere. Loaʻa ia e mālama i loko o ka friji ma ka pale o ka puka, aia kahi mamao i ka pahu manuahi. Mai hoʻokaʻawale i ka lāʻau lapaʻau!

Kāohi i ka nānā ʻana i ka lā a me ka wela nui. No ka hana ʻana i kēia, mālama nā pahu i hoʻopaʻa ʻia i loko o kahi hāmeʻa kūikawā, kahi i hoʻopili ʻia me ka mea pale.

E mālama i ka peni mau māka a wehe i ka mahana o ka lumi ma kahi wahi ʻino. ʻAʻole pono ka lōʻihi o ka mahana ma mua o 30 mau kiʻekiʻe. I mea e pale ai i nā kukui māmā, wehe mau i ka pahu pahu me kahi pāpale.

ʻO ka insulin Tresiba kahi maikaʻi maikaʻi loa o nā syringes, kahi e maʻalahi ai ke ola i nā ʻano like ʻole o ka maʻi insulin.

Pono e mālama i ka lāʻau lapaʻau i ka mahana o 2 ° a 8 ° C (i loko o ka friji) akā naʻe ʻaʻole i kokoke i kahi pahu manu. Mai hoʻokaʻawale.

No kahi peni syringe i hoʻohana ʻia a lawe ʻia paha ma kahi peni ʻole: mai mālama ʻoe i ka friji. E mālama ma ke aniani ʻaʻole he 30 ° C no 8 mau pule. Ma hope o ka hoʻohana ʻana, e pani i ka peni syringe me kahi pāpale e pale iā ia mai ka mālamalama.

Mai mālama i nā keiki.

Kuhi ʻia kekahi mau mea pono analog:

Hoʻomaopopo maikaʻi ka maʻi diabetes i nā lāʻau like ʻole. ʻO ka lōʻihi lōʻihi o ka hana a me ka hoʻokō ʻole me ka hoʻopiʻi a me ka hoʻolālā ʻana me ka liʻiliʻi. Ua kūpono ia ka lāʻau lapaʻau no nā maʻi he nui, akā ʻaʻole hiki i nā mea a pau ke hoʻokō i ka mea.

He lāʻau lapaʻau maikaʻi ʻo Tresiba no ka mālama ʻana i nā ʻano maʻi like ʻole. He kūpono no ka hapa nui o nā maʻi, kūʻai ʻia i nā pono. I ka wā o ka papa o ka maʻi, hiki i nā mea maʻi ke alakaʻi i kahi ola hoʻoikaika, me ka makaʻu ʻole no ko lākou olakino ponoʻī. He kūpono ia lāʻau lapaʻau i ka maikaʻi maikaʻi.

Irina, 23 makahiki. Ua hōʻike ʻia mākou me ka maʻi mellitus type 1 ma mua o 15 mau makahiki. Ke noho nei wau ma kahi o ka insulin no ka manawa lōʻihi a ua hoʻāʻo i nā ʻoihana like ʻole a me nā palapala hoʻokele. ʻO ka mea maʻalahi loa ʻo nā pamu insulin a me nā peni syringe.

ʻAʻole i lōʻihi loa, ua hoʻohana ʻo Tresiba Flextach ia mea. He kūpono kūpono i ka mālama ʻana, mālama a hoʻohana. Ma kahi kūpono, kūʻai ʻia nā pahu kūwili me nā ʻano like ʻole, no laila no ka poʻe e pili ana i ka lāʻau maʻi me nā ʻāpana kiʻekiʻe o ka insulin he kōkua nui kēia. A he kūpono ke kumukūʻai.

Konstantin, 54 makahiki. ʻO ka maʻi diabetes mellitus type like. Ua hoʻololi hou ʻia i insulin. Hoʻohana ʻia e inu i nā paila, no laila ua lōʻihi ka manawa e kūkulu hou ai i ka noʻonoʻo a me ke kino no nā inikini o kēlā me kēia lā. ʻO ka peni ʻo The Treshiba syringe nāna i kōkua iaʻu e hoʻohana ʻia.

He ʻūpiki loa kāna mauʻu, no laila ua aneane ʻole nā ʻōkuhi. Aia kekahi pilikia me ka hoʻoweliweli dosis. Nā mea koho paʻa. Lohe ʻoe i kahi pākuʻi ua loaʻa i ka hāmeʻa āu i hoʻonohonoho ai ma kahi kūpono a me ka mālie hana hou i ka hana. ʻO kahi mea kūpono e kūpono ai ke kālā.

Ruslan, 45 makahiki. Aia ke ʻano maʻi maʻi ʻo ka makuahine. ʻO ka manawa hou nei, ua kuhikuhi ke kauka i kahi lāʻau hou, no ka mea, ua oki ke kōkua ʻana i nā lāʻau kōniha. Ua ʻōlelo ʻo ia iā Tresiba Flekstach e kūʻai no Mama no ka mea o kona mau makahiki.

Loaʻa, a ʻoluʻolu loa i ke kūʻai mai. ʻAʻole e like me nā ampoules mau me nā syringes, kūpono loa ka peni i ka hoʻohana ʻana. ʻAʻole pono e ʻauʻau me ka helu metering a me ka hana pono. ʻO kēia pepa ka mea kūpono loa i ka pākeke.

Lapaʻau lāʻau

ʻO ka lāʻau lapaʻau Tresiba ® FlexTouch ® kahi mea hoʻopili o ka insulin o ke kanaka no ka hana lōʻihi loa, i hana ʻia e ka lāʻau o ka mea i hana ai i ka biotechnology DNA e hoʻohana nei i kahi kānana. ʻO ka lauhaʻi cerevisiae.

Nā hana hana i ka hana. Hoʻopili kūloheloheʻo Insulin degludec i ka mea nāna i hopu i ka insulin endogenous a me ka hoʻopili pū ʻana me ia, ʻike pū i kona ʻano lapaʻau e like me ka hopena o ka insulin kanaka.

ʻO ka lāʻau lapaʻau Tresiba ® FlexTouch ® kahi basal kūloko o ka insulin o ke kanaka he hana superlong, ma hope o ka s / c injection i hoʻopaʻa ʻia i ka hopena o ka multihexamers i ka depot subcutaneous, mai laila ka hoʻomau mau ʻana a me ka lōʻihi o ka pāoʻi ʻana o ka melepec insulin i ka moe vascular, e hāʻawi ana i ka hopena lōʻihi loa, ka mana o ka hopena a me ka hopena hypoglycemic paʻa o ka lāʻau. ri i ke kiʻi 1).

Ma ka manawa o 24 mau hola kiaʻi o ka hopena hypoglycemic o ka lāʻau lapaʻau i ka poʻe nāna i mālama ʻia ka nui o ka insulin degludec i hoʻokahi lā i kēlā lā, ʻo Tresiba ® FlexTouch ®, i ka hoʻohālikelike ʻana i ka glargine insulin, i hōʻike i ke kūʻokoʻa V_{e d} ma waena o ka hana i ka mua a me ka lua o 12 mau hola (AUC_{GIR0-12h, SS}/ Auc_{GIRtotal, SS} =0,5).

Kuhi 1. 24-hola mika helu infusion rate profile - C_{ai ʻo ss} insulin degludec 100 U / ml 0.6 U / kg (1987 aʻo)

ʻO ka lōʻihi o ka hana o ka lāʻau Tresiba ® FlexTouch ® ʻoi aku ma mua o nā hola 42 i loko o ka laulā hopena o ka hopena. C_{ai ʻo ss} hōʻemi ʻia ka lāʻau lapaʻau i loko o ke koko he mau lā 2-3 ma hope o ka hoʻomakeʻa ʻana o ka lāʻau lapaʻau.

Insulin degludec ma ka moku'āina C_{ai ʻo ss} hōʻike i ka emi iki (4 mau manawa) i ka hoʻohālikelike ʻana me ka glargin i nā lā i kēlā me kēia lā ka pākuʻina o nā hana hypoglycemic i kēlā me kēia lā, kahi i manaʻo ʻia e ka waiwai o ka coefficient o ka ʻano (CV) no ke aʻo ʻana i ka hopena hypoglycemic o ka lāʻau i ka wā o ka manawa doses (AUC_{GIR.τ, SS}) a i loko o ka manawa manawa mai 2 a 24 mau hola (AUC_{GIR2-24h, SS}), (ʻike i ka Papa 1.)

Ka hoʻohālikelike ʻana o nā kōpana o kēlā me kēia lā i ka hana hypoglycemic o ka lāʻau Tresiba a me ka glargine insulin i ka moku C_{ai ʻo ss} i nā maʻi me nā maʻi maʻi type 1

Nā poʻe hōʻikeʻike	Insulin degludec (N26) (CV a%)	Insulin Glargine (N27) (CV%)
Ka hoʻohālikelike o nā kikoʻī hana hypoglycemic i kēlā me kēia lā ma ke ʻano o hoʻokahi doses (AUC_{GIR, τ, SS} b)	20	82
Ka hoʻohālikelike ʻana o nā kiko hana maʻi hypoglycemic i kēlā me kēia manawa ma kahi o 2 a 24 mau hola (AUC_{GIR2-24h, SS}ne) c	22	92

a CV: coefficient of intraindividual variability,%.

b SS: ʻO ke kaila o ka lāʻau lapaʻau ma ka kūlike.

c AUC_{GIR2-24h, SS}: hopena metabola i nā hola 22 i hala o ka manawa doses (i.e. ʻaʻohe hopena ma ia mea o ka injected iv insulin i ka wā o ka hoʻomaka o ka noi clamp).

Ua hōʻoia ʻia ka pilina pili ma waena o ka hoʻonui o ka nui o ka Tresiba ® FlexTouch ® a me kona hopena hypoglycemic aoao.

ʻAʻole i hōʻike ʻia nā haʻawina i kekahi hopena koʻikoʻi o ka maʻi i ka pharmacodynamics o ka lāʻau Tresiba ® i nā mea maʻi a me nā mea maʻi ʻōpio.

He mākaukau me ka palekana

Ua hōʻike ʻia nā hoʻokolohua haukaʻi i ka emi ʻana o ka HbA_1c mai ka waiwai mua ma ka hopena o ka hoʻopaʻa ʻana ma ka ʻaoʻao o ka hopena me ka insulin Treciba ® a me ka insulin glargine 100 IU / ml. ʻO nā mea maʻi me ka maʻi diabetes mellitus type 1 (T1DM) i mālama ʻia me ka lāʻau lapaʻau Tresib ® i hōʻike i ka hopena o ka ulu ʻana o ka hypoglycemia koʻikoʻi a me ka maʻi nui a paʻa paha i ka hōʻailona hypoglycemia (ma ka laulā hypoglycemia a me ka nocturnal hypoglycemia) i hoʻohālikelike ʻia me ka glurrine insulin 100 IU / ml, e like me ka wā ka mālama ʻana i kahi pākala, a ma ka manawa mālama. ʻO nā mea maʻi me ka maʻi diabetes mellitus type 2 (T2DM) i mālama ʻia me ka lāʻau lapaʻau Tresib ® i hōʻike i ka hoʻohaʻahaʻa nui ʻana i ka ʻeha o ka hypoglycemia hōʻailona hewa a i hoʻopaʻa ʻia (ʻo ka hypoglycemia āpau a me ka hypoglycemia nocturnal) i hoʻohālikelike ʻia me ka insulin glargine (100 IU / ml), e like me ka mālama ʻana ʻO nā heluʻai, a i ka wā o ka mālama ʻana, me ka hoʻohaʻahaʻa ʻana i nā ʻeha e hōʻeha i ka hypoglycemia koʻikoʻi i ka manawa o ka wā mālama.

Ma nā haʻawina loiloi, ka nele o ka nui o ka hoʻohālikelike ʻana i nā lāʻau lapaʻau (insulin detemir a me insulin glargine) ma luna o Tresiba ® e pili ana i ka emi ʻana o HbA_1c mai ka papa hana ma ka pau ʻana o ka hoʻopaʻa ʻana. ʻO ka ʻokoʻa ka sitagliptin, i ka manawa i hōʻike ai ʻo Tresiba ® i ka mea nui o ka helu ma ka hoʻēmi ʻana i ka HbA_1c.

Hōʻike nā hualoaʻa o kahi hōʻike meta-data o ka ʻikepili ʻehiku i loaʻa nā pono o ka maʻi insulin Tresib ® me ka haʻahaʻa o ka hypoglycemia i hoʻopaʻa ʻia i ka poʻe maʻi hoʻohālikelike ʻia me ka lālani insulin glargine (100 U / ml) (Papa 2) a hoʻopaʻa ʻia i nā manawa epoglycemia nocturnal. ʻO ka emi ʻana o ke kumu o ka hypoglycemia i ka wā Tresib ® insulin therapy i loaʻa me ka hoʻokaʻawale ʻana o ka plasma plasma hoʻoliina haʻahaʻa e like me ka glargine insulin (100 IU / ml).

Nā hopena o kahi meta-analysis o nā ʻikepili i nā mahele mai o ka hypoglycemia

Kuhi helu pāʻelima (insulin degludec / insulin glargine 100 PIECES / ml)	Episodes o hoʻopaʻa ʻia hypoglycemia a
	Pau loa	Kēia lā
SD1 + SD2 (ka ʻikepili maʻamau) Nā wā mālama mālama ʻia b ʻO nā makahikiʻelemakule ≥65 mau makahiki	0.91 s	0.74 c
0.84 c	0.68 s
0,82	0.65 s
SD1 Nā wā mālama mālama ʻia b	1,1	0,83
1,02	0.75 s
SD2 Nā wā mālama mālama ʻia b ʻO ka maʻi basal wale nō i nā maʻi ma mua i loaʻa ʻole i ka insulin	0.83 s	0.68 s
0.75 s	0.62 s
0.83 s	0.64 s

He hypoglycemia i hoʻopaʻa ʻia he hanana ia o ka hypoglycemia, i hoʻopaʻa ʻia e ka helu ʻana o ka glucose glucose i kuhi ʻia b Nā Episodes o ka hypoglycemia ma hope o ka wiki 16 o ka hopena.

c Kahiki nui.

ʻAʻole i ʻike ʻia kekahi hana koʻikoʻi o nā antibodies i ka insulin ma hope o ka mālama ʻana me Tresib ® no ka manawa lōʻihi. I loko o kahi haʻawina hōʻike maʻi ma nā maʻi me T2DM i mālama pū me Tresib ® i hui pū me ka metformin, hoʻohui i ka liraglutide i hopena nui i ka hoʻoliʻina i ka HbA_1s ka kaumaha ʻana o ke kino. ʻO ka ulu ʻana o ka hypoglycemia i ka haʻahaʻa i lalo me ka hoʻopili ʻana i ka liraglutide hoʻohālikelike ʻia me ka hoʻohui o hoʻokahi ʻina hoʻokahi o ka aspart o ka insulin.

ʻO ka loiloi o ka hopena i ka CCC. E hoʻohālikelike i ka palekana cardiovascular i ka wā e hoʻohana ai i ka lāʻau lapaʻau Tresiba a me ka insulin glargine (100 PIECES / ml), ua hana ʻia kahi noiʻi. APOAOLELO pili pū me 7637 nā mea maʻi me T2DM a me kahi kiʻekiʻe nui o ka hoʻomohalaʻana i nā hanana cardiovascular.

ʻO ka palekana cardiovascular o ka hoʻohanaʻana i ka lāʻau Tresiba® i hoʻohālikelike ʻia me ka glargine insulin i hōʻoia ʻia (Kuhi 2).

N ʻO ka nui o nā mea maʻi me kahi hanana mua i hōʻoia ʻia e ka papa Hoʻolālā Hoʻolaha ma luna o ke Kōmike o nā Pono Kānāwai (EAC) i ka wā aʻo.

% ʻO ka pānaʻi o ka poʻe maʻi me ka hanana mua e hōʻoia ʻia e EAC, pili i ka nui o nā maʻi maʻi randomized.

Kiʻi 2. Hōʻuluʻulu ahi e hōʻike ana i kahi nānā ʻana o kahi māka palekana 3-point kūmole no nā hanana cardiovascular (CVSS) a me nā pauna hope cardiovascular ma kahi noiʻi. APOAOLELO.

Me ka hoʻohana ʻana o ka glargine insulin a me ka lāʻau lapaʻau Tresiba ®, he hoʻokō like i ko nā pae HbA_1s a me kahi kahe nui loa o ka ʻaihue plasma wikiwiki ma ka hoʻohana ʻana i ka lāʻau lapaʻau Tresiba ® (papa 3).

Hōʻike ʻo Tresiba ® i ka pono ma ka glargine insulin i ka ʻōlelo o ka hōʻemi haʻahaʻa o ka hypoglycemia koʻikoʻi a me kahi pae haʻahaʻa haʻahaʻa o nā mea maʻi i hoʻomohala i ka hypoglycemia koʻikoʻi. ʻO ke emi o nā ʻōpū o ka hypoglycemia nocturnal koʻikoʻi me ka hoʻohanaʻoleʻana i ka lāʻau lapaʻau Tresiba i hoʻohālikelike ʻia me ka insulin glargine (Papa Palapala 3).

Nā hopena noiʻi APOAOLELO

Ka helu kumukūʻai o HbA_1s, %

Hypoglycemia frequency (ma kēlā me kēia 100 mau makahiki i ka nānā)

ʻO ka hypoglycemia koʻikoʻi

ʻO ka hypoglycemia nocturnal koʻikoʻi 2

He pilina pilikino: 0.47 (0.31, 0.73)

ʻO ka hoʻohālikelike o nā mea maʻi me ka hoʻomohala ʻana i nā hīmeni o ka hypoglycemia (% o nā mea maʻi)

ʻO ka hypoglycemia koʻikoʻi

Koho Hōʻailona: 0.73 (0.6, 0.89)

Nā poʻe hōʻikeʻike	Tresiba ® 1	Insulin Glargine (100 PIECES / ml) 1
Iniiana HbA_1s	8,44	8,41
Mau makahiki 2 o ka lapaʻau	7,5	7,47
Ka ʻokoʻa: 0.008 (−0.05, 0.07)
Ka holi ʻana i ka glucose glucose, mmol / L
Initial waiwai	9,33	9,47
Mau makahiki 2 o ka lapaʻau	7,12	7,54
ʻOkoʻa: −0.4 (−0.57, −0.23)
3,7	6,25
He pilina pilikino: 0.6 (0.48, 0.76)
0,65	1,4
4,9	6,6

1 Ma kahi o ka maʻamau no ka mālama o ka maʻi maʻi a me nā maʻi cardiovascular.

2 Hōʻeha hypoglycemia pōʻino kekahi hypoglycemia i loko o ke kau manawa o ka lā ma waena o 0 a 6 ʻAo.

Na keiki a ʻōpio. I loko o kahi haʻawina loea i nā keiki a me nā wā'ōpiopio me ke maʻi type 1, ke hoʻohana ʻana o Tresiba ® i hoʻokahi manawa i ka lā i hōʻike i kahi emi like o ka HbA_1s e ka 52nd pule a i ʻole he keu, he hōʻemi e hoʻemi ana i ka glucose o ka plasma wikiwiki e pili ana i nā waiwai mua i ka hoʻohālikelike ʻia me ka hoʻohana ʻana i ka lāʻau lapaʻau hoʻohālikelike (ʻo ia ka insulin detemir 1 a i ʻole 2 mau manawa i kahi lā). Ua hoʻokō ʻia kēia hopena me ka hoʻohana ʻana i ka lāʻau lapaʻau ʻo Tresiba i kēlā me kēia lā he 30% emi ma lalo o ka insulin detemir. ʻO ke alapine (ʻike i kēlā me kēia makahiki hānā o ka ʻike) o nā ʻeha o ka hypoglycemia koʻikoʻi (ka wehewehe ʻana i ka International Society for Study of Diabetes Mellitus (DM) i nā keiki a me nā ʻōpio. (ISPAD), 0.51 i hoʻohālikelike ʻia me 0.33), hoʻopaʻa ʻia hypoglycemia (57.71 hoʻohālikelike ʻia me 54.05) a ua hōʻoia ʻia i ka pō hypoglycemia (6.03 hoʻohālikelike ʻia me 7.6) i hoʻohālikelike ʻia me Tresiba ® a me ka insulin detemir . ^ E Ha yM. I nā hui mālama ʻelua i nā keiki he 6 a 11 paha makahiki, ʻoi aku ka nui o ka ulu ʻana o ka hypoglycemia ma mua o nā hui ʻē aʻe. Aia i kahi kiʻekiʻe kiʻekiʻe o ka hypoglycemia koʻikoʻi i nā keiki i hala 6 a 11 paha i ka hui Tresiba ®. ʻO ka pinepine o nā ʻōhumu o ka hyperglycemia me ka ketosis i haʻahaʻa loa me ka hoʻohana ʻana i ka lāʻau lapaʻau Tresiba i hoʻohālikelike ʻia me ka mālama ʻana me ka insulin detemir, 0.68 a me 1.09, kēlā me kēia. ʻO ka maʻamau, ʻano a me ka paʻakikī o ka hopena maikaʻiʻole i ka heluna o nā maʻi pediatric ʻaʻole i ʻokoʻa i kēlā poʻe i ka lehulehu ākea o nā mea maʻi me ka maʻi maʻi. Lele ʻo ka ulu ʻana o ka antiibody a ʻaʻohe waiwai koʻikoʻi ʻo ia. ʻO ka ʻikepili e pili ana i ka pono a me ka palekana i nā wā'ōpiopio me T2DM ua lawe ʻia i luna e pili ana i ka ʻikepili i loaʻa mai ka poʻe ʻōpio a me nā maʻi makua me ka T1DM a me nā maʻi pākeke me T2DM. Loaʻa nā hopena iā mākou e hōʻike i ka lāʻau lapaʻau Tresiba ® no ka mālama ʻana i nā ʻōpiopio me ka maʻi diabetes 2 type.

Nā Hoʻohui

hoʻonui ka naʻau pilikino i ka mea ikaika a i ʻole kekahi o nā mea kōkua o ka lāʻau lapaʻau,

ka manawa o ka hapai, ka manawa o ka umauma (ʻaʻohe mea ʻike loea me ka hoʻohana ʻana i ka lāʻau lapaʻau i ka wahine i ka wā hāpai a me ka hānai ʻana),

makahiki mai na keiki a hiki i ka 1 makahiki mai ʻaʻole i mālama ʻia nā hoʻokolohua lapaʻau i nā keiki ma lalo o 1 mau makahiki.

Nā hopena hopena

ʻO ka hopena maʻamau e hōʻike ʻia i ka wā o ka mālama ʻana me ka insulin degludec he hypoglycemia (ʻike ʻO ka wehewehe ʻana i nā ʻano kū maikaʻi pili ʻole).

ʻO nā hopena āpau a pau i hōʻike ʻia ma lalo nei, e pili ana i ka ikepili mai ka hoʻopaʻa ʻana ma nā maʻi maʻi, e hoʻopaʻa ʻia e like me MedDRA a me nā hoʻonohonoho hoʻonohonoho. ʻO ka hopena o nā hopena ʻili ke kau ʻia i ka wā pinepine (≥1 / 10), pinepine (≥1 / 100 a ® FlexTouch ® mau hopena hypersensitivity (e pili ana i ka ʻōpū o ke alelo a i ʻole nā lehelehe, ka ʻōpū, ke kala, nā ʻeha a me ka ʻeha) a me urticaria luhi pinepine ʻia

Hypoglycemia. E hoʻomohala ʻia inā he kiʻekiʻe loa ka nui o ka inika e pili ana i ka pono o ka mea maʻi i ka insulin. ʻO ka hypoglycemia koʻikoʻi hiki ke alakaʻi i ka nalowale o ka ʻike a / a i nā mea hoʻi i koi ʻia, ka wā hoʻokaʻawale a ʻaʻole hoʻi i hoʻopoina i ka hana o ka lolo, ʻo ka make. Nā hōʻailona o ka hypoglycemia, ma ke ʻano he kānāwai, hoʻomohala koke. Hoʻopili kēia i ka minamina anuanu, ka pallor o ka pehu, hoʻonui nui i ka momona, ka hopohopo a me ka haʻalulu, ka hopohopo, nāwaliwali ʻole a nāwaliwali, ka hōʻeha, ka hoʻokaʻawale ʻana, ka hiamoe, ka pōloli nui, ka pōkole blurred, hōʻeha, ka ʻeha, a i nā palpitations.

Lipodystrophy (me ka lipohypertrophy, lipoatrophy) e ulu ma luna o ka pūnaewele wili. ʻO ka hana kūpono me nā lula no ka hoʻololi ʻana i ka pae injection i loko o ka wahi anatomical like me ke kōkua e hōʻemi i ka hopena o ka hoʻomohala ʻana i kēia hopena ʻino.

Nā wahi hōʻike ma ka wahi ʻōlelo. Ua hōʻike ʻia nā mea maʻi me Tresiba ® FlexTouch ® i ka hopena ma ka wahi i hiki aku ai ka maʻi (hematoma, ʻeha, ʻehaʻāina, erythema, nodul a me ka huehue, ka ʻāʻī ʻana o ka ʻili, ʻeha, ka huhū a me ka paʻa ʻana ma ka wahi i ʻōlelo ʻia ai). ʻO ka hapanui o nā pane ma ka pūnaewele ʻoi aku ka liʻiliʻi, ka wā lewa, a me ka nalowale me ka hoʻomau ʻia ʻana o ka mālama ʻana.

Na keiki a ʻōpio. Ua hoʻohana ʻia ka lāʻau lapaʻau ʻo Tresiba i nā keiki a me nā ʻōpio ma lalo o nā makahiki 18 i hoʻopaʻa ʻia i nā waiwai pharmacokinetic. Ma kahi noi lōʻihi lōʻihi i nā keiki i makahiki 1 a hiki i ka 18 makahiki, ua hōʻike ʻia ka palekana a me ka pono. ʻO ka pinepine o ka ʻaha, ka ʻano a me ka paʻakikī o ka hopena ʻokoʻa i ka heluna o nā maʻi pediatric ʻaʻole i ʻokoʻa i ka poʻe i ka poʻe ākea o nā maʻi me ka maʻi maʻi (e nānā He mākaukau me ka palekana).

Nā hui ahonui kūikawā

Ma nā hoʻokolohua lapaʻau, ʻaʻohe ʻike ʻē aʻe i ke alapine, ʻano, a i ʻole ka paʻakikī o nā hopena ʻino i nā mea maʻi ma nā mea maʻi a me nā mea maʻi me ka renal a i ʻole ka hana hepatic ma ka lehulehu kanaka maʻi.

Hoʻohui

Nui kekahi mau lāʻau lapaʻau e pili ana i ka metabolism glucose.

Pono ka hōʻemi i ka insulin. ʻO PHGP, GLP-1 agon reseptor receptor, MAO inhibitors, non-selective beta-blockers, ACE inhibitors, salicylates, anabolic steroid and sulfonamides.

Hiki i ka pono ke hoʻonui i ka insulin: Contraceptives ka waha oralal, diuretics thiazide, corticosteroids, thyroid hormones, sympathomimetics, somatropin a danazole.

Nā māka hua Beta may mask hōʻailona o hypoglycemia.

Octreotide / Lanreotide hiki ke hoʻonui a hoʻēmi i ka pono o ke kino no ka insulin.

Etanol (inu wai) hiki iā lāua ke hoʻoikaika a hoʻemi i ka hopena hypoglycemic i ka insulin.

Lauluu. ʻO kekahi mau lāʻau lapaʻau, inā e hoʻohui ʻia iā Tresib ® FlexTouch ®, hiki ke luku ʻia. ʻAʻole hiki ke hoʻohui ʻia ka lāʻau lapaʻau Tresiba ® FlexTouch ® i nā hopena infusion. ʻAʻole hiki iā ʻoe ke hoʻohui i ka lāʻau lapaʻau Tresiba ® FlexTouch ® me nā lāʻau lapaʻau ʻē aʻe.

ʻLoe a me ke kākele

S / c Ma kahi o kahi lā i kēlā me kēia lā, akā ʻoi aku ka maikaʻi o ka lawelawe ʻana i ka lāʻau lapaʻau i ka manawa like i kēlā me kēia lā.

ʻO ka lāʻau lapaʻau Tresiba ® FlexTouch ® kahi mea hoʻohui o ka insulin ultra-lōʻihi ka hana.

Tresiba ® FlexTouch ® ka lōʻihi o ka hoʻonaʻauao insulin.

I nā maʻi me ka maʻi type 2, hiki i ka Tresiba ® FlexTouch ® ke hoʻohana 'ia e like me ka monotherapy a i hui pū ʻia me nā lāʻau hypoglycemic waha (PHGP), e like me nā ponaid e like me peptide-1 receptor agonists (GLP-1), a me ka bolus insulin (e ʻike. He mākaukau me ka palekana).

No nā mea maʻi me ka maʻi type 1, ua ʻōlelo ʻia ʻo Tresiba ® FlexTouch ® e hui pū me ka insulin / ultrashort e uhi i ka pono o ka insulin prandial.

E hoʻoholo pono ʻia ke ʻano o ka maʻi ʻo Tresiba ® FlexTouch ®, e like me nā pono o ka mea maʻi. E hoʻokala i ka mana glycemic, kahi e pono ai e hoʻoponopono i ka nui o ka lāʻau lapaʻau e pili ana i ka helu o ka glucose plasma glucose.

E like me kēlā me ka hoʻomākaukau ʻana i nā insulin, pono ke hoʻoponopono ʻia ʻana o ka hoʻoponopono Tresiba® FlexTouch® e pono ai i ka hoʻomaikaʻi ʻana i ka hana kino o ka mea maʻi, hoʻololi i kāna kīʻai maʻamau, a i ʻole me kahi maʻi concomitant.

Tresiba ® FlexTouch ® 100 U / ml a me Tresiba ® FlexTouch ® 200 UNIT / ml

Loaʻa ka Tresiba ® FlexTouch ® i ʻelua mau hopena. No nā hewa ʻelua, ʻo ka pāo e pono ai ka lāʻau lapaʻau ke kau ʻia i nā mahele. Eia nō naʻe, ʻokoʻa ka pae mahele ma waena o ʻelua mau papa i ka hoʻomākaukau o Tresiba ® FlexTouch ®.

1. Tresiba ® FlexTouch ® 100 PIECES / ml hiki iā ʻoe ke komo i nā helu mai 1 i 80 mau pūʻulu i hoʻonui ʻia o 1 pūʻulu i hoʻokahi maʻi.

2. ʻO Tresiba ® FlexTouch ® 200 PIECES / ml e hiki iā ʻoe ke komo i nā inika mai 2 a 160 PIEʻEA i nā waihona o 2 PIECES i hoʻokahi injection. Aia ka nui o ka insulin i ka hapalua o ka nui o ka hoʻonā i hoʻohālikelike ʻia i ka hoʻomākaukau ʻana o ka insulin basal 100 IU / ml.

Hōʻike ka counter counter i ka helu o nā waihona, he mau kapa ʻole; ʻaʻohe mea pono ke helu hou aʻe i ka lāʻau i ka wā e hoʻoneʻe ana i nā maʻi i kahi maʻi hou.

Hoʻopau ʻia ka dimenea hoʻopaʻi ʻia

I nā hihia ʻaʻole i hiki ʻole ke hoʻolaha ʻana o ka lāʻau i ka manawa like, hiki iā Tresiba ® FlexTouch ® ke hiki iā ʻoe ke hoʻololi i ka manawa o kona hoʻokele ʻana (e nānā He mākaukau me ka palekana) I ka manawa like, ʻo ka manawa ma waena o nā inikini he liʻiliʻi loa he mau hola 8. Ua ʻike ka maʻi maʻi i ka neʻe ʻana o ka pehu nāu o ka lāʻau Tresiba ® FlexTouch ® i loko o nā keiki a keu ʻole ka ʻōpio.

Ke kīia ʻia nei e hiki i kēlā mau mea maʻi e poina e lawelawe koke i ka dosis o ka insulin e komo i loko o ka make i ka wā e loaʻa ai, a hoʻi hou i ka manawa maʻamau no ka hoʻoponopono o kēlā me kēia lā o ka lāʻau.

ʻO ka ʻōmua mua o ka lāʻau ʻo Tresib ® FlexTouch ®

ʻO nā maʻi me ka T2DM. ʻO ka ʻōnaʻi o ka lā mua a me ke ʻano o Tresiba ® FlexTouch ® he 10 mau mea, a ukali ʻia e ke koho ʻana i kahi kū hoʻokahi o ka lāʻau.

ʻO nā maʻi me ka maʻi maʻi type 1. ʻO ka lāʻau Tresiba ® FlexTouch® e kuhikuhi i hoʻokahi manawa i ka lā i hui pū me ka insulin prandial, ka mea i mālama ʻia me ka meaʻai, e ukali ʻia e ke koho ʻana i kahi kū hoʻokahi o ka lāʻau.

Ke hoʻololi nei mai nā hoʻomākaukau ʻē aʻe o ka insulin

Hoʻomaopopo ka mālamaʻana i ke kaohi o ke koko i ka wā o ka neʻe ʻana a i loko o nā pule mua o ka maʻi me Tresib ® FlexTouch ® i ʻōlelo ʻia. Ke hoʻoponopono ʻana i ka therapy hypoglycemic concomitant (ka manawa a me ka manawa o ka hoʻokele ʻana o ka hoʻomākaukau ʻana i ka insulin a me ka ultrashort hoʻomākaukau a i ʻole kekahi manawa e hoʻohana ʻia nā lāʻau hypoglycemic) pono paha.

ʻO nā maʻi me ka T2DM. Ke hoʻoneʻe nei ʻo Tresiba ® FlexTouch ® i ka poʻe maʻi me ka maʻi type kīkē 2 e pae ana ma ka basal a i ʻole basal-bolus o ka hoʻoponopono ʻana i ka insulin a i ʻole ka hoʻoponopono ʻia ʻana me ka insulins insulin i hana kūlohelohe / hoʻohuihui pono ʻia, ʻo ka hopena o Tresiba ® FlexTouch ® e pono ke kau ʻia ma ka hopena o ka insulin basal a i loaʻa i ka mea maʻi ma mua o ka neʻe ʻana i kahi ʻano o ka insulin hou, e like me ke kumumanaʻo "pākahi 'unit", a laila hoʻoponopono ʻia e like me nā mea pono āpau o ka mea maʻi.

Pono e hāʻawi ʻia ka hoʻemi ʻana o 20% o ka nui o ka insulin basal o mua, a ukali ʻia e hoʻoponopono ʻia e like me nā pono o ka mea maʻi i nā maʻi aʻe.

- ka lawe mai i ka insulin basal, i lawelawe ʻia i nā manawa 2 i ka lā, i ka lāʻau lapaʻau Tresiba ® FlexTouch ®,

- ka neʻe ʻana mai ka glargine insulin (300 PIECES / ml) i ka lāʻau lapaʻau Tresiba ® FlexTouch ®.

ʻO nā maʻi me ka maʻi maʻi type 1. ^ E Ha yM. Ke hoʻoneʻe nei i nā mea maʻi me T1DM i Tresiba ® FlexTouch ®, kahi hōʻemi haʻahaʻa o 20% o ka laʻu o mua i ka insulin basal a i ʻole ke ʻano o ka basal o ka hoʻomau i nā infusions s / c insulin (PPII). A laila, hoʻoponopono ʻia ka hopena e like me nā hemahema o kēlā me kēia maʻi o ka mea maʻi e pili ana i nā kuhikuhi glycemia.

ʻO ka hoʻohana ʻana o Tresiba ® FlexTouch ® i hui pū me nā agonist receptor GLP-1 i nā maʻi me nā maʻi maʻi type 2. I ka manawa ua hoʻohui ʻia ʻo Tresiba ® FlexTouch ® i ka lāʻau lapaʻau me ka agonist receptor GLP-1, ʻo ka ʻōnaehana hoʻonaʻau mua o kēlā me kēia lā he 10 mau mea e ukali ʻia e ka hoʻoponopono kūlohelohe kūʻokoʻa.

Ke hoʻohui nei i nā agonist o nā mea hoʻokipa GLP-1 e mālama ai me Tresib ® FlexTouch ®, e noʻonoʻo ʻia e hōʻemi i ka hopena o Tresib ® FlexTouch ® e 20% e hōʻemi i ka hopena o ka hypoglycemia.

Ma hope iki, pono ke hoʻoponopono ʻia i ka lāʻau maʻi.

Nā hui ahonui kūikawā

He ʻelemakule (ma mua o 65 mau makahiki). Hiki ke hoʻohana ʻo Tresiba ® FlexTouch ® i nā maʻi maʻi maʻi. Pono ka nānā ʻana o ke kaila o ke koko a ʻike pono ʻia ka ʻōkole o ka insulin (ʻike ʻia "Pharmacokinetics").

ʻO ka hemahema o ka pēpē a me ka hana ate. Hiki ke hoʻohana ʻo Tresiba ® FlexTouch ® i nā mea maʻi me ka mōʻī aaleka ʻole. Pono ka nānā ʻana o ke kaila o ke koko a ʻike pono ʻia ka ʻōkole o ka insulin (ʻike ʻia "Pharmacokinetics").

Na keiki a ʻōpio. Hiki ke hoʻohana ʻia ka lāʻau lapaʻau Tresiba ® FlexTouch ® e hoʻomaʻamaʻa i nā wā ʻōpio a me nā keiki i ʻoi aku ma mua o ka 1 makahiki (ʻike He mākaukau me ka palekana) Ke hoʻololi nei mai ka basal insulin a me Tresiba ® FlexTouch ®, pono i kēlā me kēia kūlana ke nānā i ka pono o ka hoʻemi ʻana i ka nui o ka pae basal a me ka bolus insulin e hōʻemi i ka hopena o ka hypoglycemia (ʻike. "ʻAoʻao ʻaoʻao").

ʻO ka lāʻau ʻo Tresiba ® FlexTouch ® ka mea i manaʻo ʻia no ka hoʻokele sc wale nō.

ʻAʻole hiki ke hoʻokele ʻia ka lāʻau lapaʻau Tresiba ® FlexTouch ® iv. hiki kēia i nā hypoglycemia koʻikoʻi.

ʻAʻole hiki ke hoʻokomo ʻia ka lāʻau ʻo Tresiba ® FlexTouch ® i loko o ka / m, no ka i kēia hihia, ua loli ka hoʻololi ʻana o ka lāʻau.

ʻAʻole pono e hoʻohana ʻo Tresiba ® FlexTouch ® i loko o kahi pamu insulin.

Hoʻohana ʻia ka lāʻau lapaʻau Tresiba ® FlexTouch ® subcutaneously ma ka ʻūhā, nā poʻohiwi a me ka ʻaoʻao o ka ʻōpū.

Pono e hoʻololi ʻia nā pūnaewele injection i loko o ia ʻāina anatomical e hōʻemi i ka hopena o ka lipodystrophy.

ʻO Tresiba ® FlexTouch ® ka peni syringe paʻa mua i hana ʻia no ka hoʻohana pono ʻana me NovoFine ® a i ʻole nā manamana o ka inikua a NovoTvist ®.

ʻO Tresiba ® FlexTouch ® 100 PIECES / ml e hiki iā ʻoe ke komo i nā inika mai 1 i 80 mau pūʻulu i hoʻonui ʻia o 1 pūʻulu i hoʻokahi maʻi.

ʻO Tresiba ® FlexTouch ® 200 PIECES / ml e hiki ai iā ʻoe ke komo i nā inika mai ka 2 a i ka 160 PIECES i nā hōʻuluʻulu o 2 PIECES i hoʻokahi injection.

Nā ʻōkuhi no ka mea maʻi

Pono ʻoe e heluhelu pono i kēia mau ʻōlelo aʻo ma mua o ka hoʻohana ʻana i ka peni syringe penikala mua iho ʻia. Inā ʻaʻole pono ka mea maʻi i nā ʻōlelo aʻoaʻo, hiki iā ia ke lawelawe i ka lawa ʻole a i ʻole nui hoʻi o ka nui o ka insulin, hiki iā ia ke hana i kahi pālahalaha kiʻekiʻe a emi ʻole paha.

E hoʻohana wale i ka peni ʻo ka syringe wale nō ma hope o ke aʻo ʻana o ka mea maʻi i mea e hoʻohana ai ma lalo o ke alakaʻi a ke kauka a kauka paha.

Pono ʻoe e nānā mua i ka lepili ma ka lehele penikala ʻiwikoli ke ʻike i ʻike pū ʻia i loko o Tresiba ® FlexTouch ® 100 PIECES / ml / Tresiba ® FlexTouch ® 200 PIECES / ml, a laila e nānā pono i nā kiʻi i lalo, e hōʻike ana i nā kikoʻī o ka penina ʻili. a me ka mauʻu.

Inā hele hewa ka maʻi a loaʻa iā ia nā pilikia koʻikoʻi a ʻaʻole hiki iā ia ke hoʻokaʻawale i waena o nā helu ma ka counter counter, ʻaʻole e hoʻohana i kahi penu syringe me ke kōkua ʻole. Hiki ke kōkua ʻia kēlā mea maʻi e kekahi kanaka me ka loaʻa ʻole o ka ʻike maka ʻole, hoʻomaʻamaʻa ʻia i ka hoʻohana pono ʻana o nā peni syringe penikala mua ʻia.

Tresiba ® FlexTouch ® 100 U / ml - kahi penikala syringe paʻa mua piha 300 PIECES o ka insulin degludec. ʻO ka nui o ka nui ma mua o ka mea maʻi e hoʻonoho ai i nā ʻāpana 80 i nā nui o ka 1 ʻāpana.

Tresiba ® FlexTouch ® 200 UNITS / ml - kahi penikala syringe paʻa mua a loaʻa 600 PIECES o ka insulin degludec. ʻO ka nui loa e hiki i ka mea maʻi ke hoʻonohonoho i nā ʻāpana he 160 i ka nui o nā hui 2.

Hoʻolālā ʻia ka syringe pen no ke hoʻohana ʻana me nā pono ponoi ʻo NovoFayn ® a i ʻole NovoTvist ® a hiki i 8 mm lōʻihi. ʻAʻole komo i nā pono ponoʻi i loko o ka pulu.

Hoike waiwai. ^ E Ha yM. E hoʻolohe i ka ʻike i ʻike ʻia e like me mea nui, he mea koʻikoʻi loa ia no ka hoʻohana pololei ʻana i ka peni ʻoring.

Kiʻi 3. Tresiba ® FlexTouch ® 100 U / ml.

Kiʻi 4. Tresiba ® FlexTouch ® 200 U / ml.

I. ʻO ka hoʻomākaukau ʻana i ka peni no ke hoʻohana

E nānā i ka inoa a me ka maʻa ma ka loulou o ke syringe peni e maopopo ai he mea nona ka Tresiba ® FlexTouch ® 100 IU / ml / Tresiba ® FlexTouch ® 200 IU / ml. He mea koʻikoʻi kēia inā hoʻohana ka mea maʻi i nā ʻano ʻāpana o nā insulins. Inā kuhi ʻo ia i kekahi ʻano o ka insulin, e piʻi nui paha ke koʻikoʻi o ke koko.

A. E wehe i ka pāpale mai ka peni ʻili.

B. E hōʻoia o ka mākaukau ʻana o ka insulin i ka penikala ʻiwīwī. E nānā ma o ka puka makani o ka nui o ke koena o ka insulin. Inā heʻeleʻele ka lāʻau lapaʻau, ʻaʻole hiki ke hoʻohana ʻia ka penu syringe.

C. E lawe i kahi pono kīkaha hou a wehe i ka lāʻau pale.

D. E kau i ka pulima ma ka penu mauʻu a me ka ʻihi iā ia ke kau ʻia nei ka jarika ma luna o ka peni ʻuli.

E. Hoʻokuʻu i ka pāpale waho o ka pono, akā ʻaʻole e hoʻokaʻawale. Pono e loaʻa ma hope o ka hoʻonā ʻana ke hoʻopau pono ʻana i ka pono mai ka peni ʻo ka syringe.

F. E wehe a hoʻokuʻu i ka pāpū pono kūloko. Inā hoʻāʻo ka mea maʻi e hoʻihoʻi i ka pūloko i loko i ka pū, pono paha ia i ka ʻoki.

Lūlū ʻia ka insulin e hū ʻia ma ka hopena o ka pono. ʻO kēia ka mea maʻamau, akā pono e nānā hou ka mea maʻi no ka insulin.

Nā ʻike nui. Pono e hoʻohana pono i kahi pono kuahi no kēlā me kēia inake. ʻO kēia hōʻemi i ka hopena o ka maʻi maʻi, ka maʻi, ka leakage o ka insulin, ka pale ʻana i ka pono a me ka hoʻopuka ʻana mai i ka hewa o ka lāʻau.

Nā ʻike nui. Mai hoʻohana wale i ka pono inā ke kūleʻa a ʻālo paha.

II. Hōʻike Insulin

G. Ma mua o kēlā me kēia ʻino, pono nā ʻike intake insulin. E kōkua kēia i ka mea maʻi e hōʻoia e hoʻokō pono i ka make o ka insulin.

E hōʻuluʻulu i nā 2 o nā mea lapaʻau ma ka huli ʻana i ka mea koho koho kō. Hōʻike i ka counter inane e hōʻike ana i ka "2".

H. Ke paʻa nei i ka peni ʻo ka syringe me ka pulima ʻoi, e pihi maʻalahi i ka piko o ke kuʻu ʻākau nui i kekahi mau manawa me kou manamana lima e lele i nā ʻōpū o ka lewa.

I. Pomi i ka pihi hoʻomaka a hoʻopaʻa i kēia kūlana a hoʻi mai ka paʻakai i nā "0". “0” aia nō i mua o ka mākaʻi kuhikuhi. Pono e hū ʻia kahi lua o ka insulin i ka hopena o ka pono. Hiki ke lūlū kahi liʻiliʻi o ka lewa i ka hope o ka pono, akā ʻaʻole ia e kau ʻia. Inā ʻaʻole ʻike ka kahe o ka insulin ma ka hopena o ka pūlea, e hana hou i nā hana G - I (ʻanuʻu II), akā, ʻaʻole iʻoi aku ma mua o 6 mau manawa.

Inā ʻaʻole ʻike ʻia ka hāʻule o ka insulin, e hoʻololi i ka pono a hana hou i nā hana G - I hou hou (Pauku II).

Inā ʻaʻole ʻike ʻia kahi puna o ka insulin i ka hope o ka hāleu, mai hoʻohana i kēia penikala syringe. E hoʻohana i kahi penikala syringe hou.

Nā ʻike nui. Ma mua o kēlā me kēia inikini, e ʻike pono ka hāʻule ʻana o ka insulin i ka hope o ka pono. Hoʻomaopopo kēia i ka lawe ʻana i ka insulin. Inā ʻaʻole ʻike ʻia kahi hāʻule o ka insulin, ʻaʻole e hoʻokele ʻia ka make, ʻoiai ke neʻe ka mole. E hōʻike paha kēia i ka palaka ʻia a hōʻino ʻia paha.

Nā ʻike nui. Ma mua o kēlā me kēia inikini, pono e nānā pono ʻia ka hoʻohana ʻana i ka insulin. Inā ʻike ʻole ka mea maʻi i ka komo ʻana o ka insulin, ʻaʻole hiki iā ia ke hoʻokō i ka lawa ʻole o ka insulin a i ʻole a pau loa, hiki iā ia ke alakaʻi i kahi kiʻekiʻe kiʻekiʻe o ka glucose koko.

III. Ka hoʻonohonoho hoʻonohonoho ʻana

J. Ma mua o ka hoʻomaka ʻana i ka hoʻonākiʻi, e hoʻomaopopo ʻoe ua hoʻonohonoho ke kāpena ʻae i ka "0". “0” aia nō i mua o ka mākaʻi kuhikuhi. E hoʻokau i ka mea koho koho e kau i ka pona i noi ʻia e ke kauka.

ʻO ka nui loa o ka maʻi e kau ai i ka mea maʻi he 80 a 160 IU (no Tresiba ® FlexTouch ® 100 IU / ml a me Tresiba ® FlexTouch ® 200 IU / ml, ma kēlā me kēia).

Inā hoʻonohonoho ʻia ka nui o ka hewa, hiki i ka mea maʻi ke hoʻohuli i ka mea koho ma mua a i hope paha a hiki i ka pae ʻana o ka pae kūpono.

Hoʻonoho ka mahele koho i ka helu o nā unahi. ʻO ka counter wale nō ka palena a me nā kuhikuhi ʻona e hōʻike i ka nui o nā hui o ka insulin i ka papalena āu i lawe ai.

ʻO ka nui loa o ka maʻi e kau ai i ka mea maʻi he 80 a 160 IU (no Tresiba ® FlexTouch ® 100 IU / ml a me Tresiba ® FlexTouch ® 200 IU / ml, ma kēlā me kēia).

Inā he koena ka nui o ka insulin ma ka penikala ʻiwikoa ʻoi aku ka liʻiliʻi ma mua o 80 a 160 PIECES (no Tresiba ® FlexTouch ® 100 PIECES / ml a me Tresiba ® FlexTouch ® 200 PIECES / ml, pūpono), e kū ka counter counter i ka helu o nā kōmina i waiho ʻia i ka peni syringe.

I kēlā me kēia manawa e huli ka mea koho, hoʻōla ʻia nā kaomi, ʻalo ke kani o nā kaomi ma ka ʻaoʻao e huli ana ka mea koho ma ke alo (ke alo i mua, a i hope a i ʻole ka hōʻuluʻulu o ka nui i nā helu o ka insulin i waiho ʻia i ka peni mau syringe). ʻAʻole helu ʻia nā liki kēia.

Nā ʻike nui. Ma mua o kēlā me kēia inikini, pono ia e nānā i nā ʻāpana he nui o ka insulin i kaha ʻia e ka mea maʻi ma ka counter counter a me ka hōʻailona kuhikuhi. Kaua e helu i nā pākuʻi o ka peni ʻiweluʻe. Inā hoʻonohonoho ka mea maʻi a hōʻike i ka hala ʻole hewa, ʻo ke ʻano o ka glucose i ke koko e lilo a kiʻekiʻe a haʻahaʻa paha.

Hōʻike ka inika kaulike insulin i ka nui o ka insulin e waiho ana i ka penehina syringe, no laila hiki ʻole iā ia ke hoʻohana ʻia kahi nui o ka insulin

IV. ʻO ka hoʻokolohua Insulin

K. E hoʻokomo i kahi pūkaʻu ma lalo o kou ʻili e hoʻohana ana i ke ʻano o ka injection ua ʻōlelo ʻia e kāu kauka a i kahu paha. E hōʻoia i ka pae ʻana o ka mahele ma kahi o ke ʻano ʻike o ka mea maʻi. Mai hoʻopā i nā counter dosis me kou mau manamana lima. Hoʻopilikia paha kēia i ka ʻeha. E kaomi i ka pihi hoʻomaka ma ke ala a paʻa i kēia kūlana a hiki ke hōʻike ʻia ke ana o ka mahele "0". "0" pono kūpono i ka hōʻailona o ka pauku, ʻoiai hiki ke lohe a lohe paha i kahi kaomi.

Ma hope o ke kōkō, e haʻalele i ka nuku ma lalo o ka ʻili (ma ka liʻiliʻi o 6 s) e hōʻoia i ka pākaʻi piha ʻana o ka insulin.

L. E waiho pono i ka pono ma lalo o ka ʻili e ka huki ʻana i ka ʻāʻā maʻa.

Inā hele mai ke koko ma ke kahua loiloi, e kaomi malū i kahi kao ʻeke i kahi wahi i ʻōlelo ʻia. Mai hamo i ke kahua kaila.

Ma hope o ka kū ʻia ʻana o ka huakaʻi, ʻike paha ke kanaka i ka hāʻule o ka insulin i ka hope o ka pūpū. He maʻamau kēia a ʻaʻole pili i ka wī o ka lāʻau lapaʻau e mālama ʻia nei.

Nā ʻike nui. E ʻike mau i ka counter dosis e ʻike ai e ʻike ʻia ehia mau nui o ka insulin. E hōʻike i ka counter counter ka helu maoli o nā kikowaena. Kaua e helu i nā helu o nā pihi ma ka peni ʻoiwela. Ma hope o ka hoʻonāukiuki, e paʻa i ka pihi hoʻomaka a hoʻi i ka pane o ke ʻano e hoʻi ana i "0". Inā ua oki ka palena wai ma mua o ka hōʻike ʻana i ka "0", ʻaʻole i komo ka make o ka nui o ka insulin, hiki iā ia ke hana i ke kaʻe o ka glucose i loko o ke koko.

V. Ma hope o ka pau ʻana o ka ʻae ʻana

M. E hoʻokomo i ka pāpale ponoʻu ʻokoʻa ma kahi pālahalaha, e hoʻokomo i ka hope o ka pono i loko o ka pāpale me ka ʻole e hoʻopā a me ka pono.

N. I ka manawa e komo ai ka pono ma ka pāpale, e hoʻokomo pono i ka pāpale i ka pono. E wehe i ka pono a hoʻokaʻawale iā ia, nānā i nā hana palekana.

A. Ma hope o kēlā me kēia hōkui, kau i kahi pāpale ma ka peni e pale ai i ka insulin e loaʻa ana mai ka ʻike i ka mālamalama.

E kiola aku i ka pono ma hope o kēlā me kēia inake. ʻO kēia hōʻemi i ka hopena o ka maʻi maʻi, ka maʻi, ka leakage o ka insulin, ka pale ʻana i ka pono a me ka hoʻopuka ʻana mai i ka hewa o ka lāʻau. Inā clogle ka lāʻau, ʻaʻole hiki i ka mea maʻi ke kau i ka insulin.

Lūku i ka peni ʻo ka peni ʻoʻee i hoʻohana pono ʻia e like me ke kauka ʻana i kāu kauka, kahu, kauka lāʻau, a i ʻole nā hoʻoponopono ʻāpana.

Nā ʻike nui. Mai hoʻāʻo iki e hoʻihoʻi i ka pūlū i loko i ka pū. ʻEkiki paha ka mea maʻi.

Nā ʻike nui. Ma hope o kēlā me kēia inikini, hoʻoneʻe mau i ka pūkaʻi a mālama mai i ka penu ʻo ka syringe me ka nila pono ʻole e laha. ʻO kēia hōʻemi i ka hopena o ka maʻi maʻi, ka maʻi, ka leakage o ka insulin, ka pale ʻana i ka pono a me ka hoʻopuka ʻana mai i ka hewa o ka lāʻau.

VI. Ehia mau insulin e waiho?

P. ʻO ke koena o ka insulin e hōʻike ana i ka nui o ka nui o ka insulin i waiho i ka peni.

R. I ʻike maopopo i ka hapa nui o ka insulin i ka peni, pono ʻoe e hoʻohana i kahi pākēnē: e hoʻohuli i ka mea koho pono a hiki i ke kū ʻana o ka make. Inā hōʻike ka counter counter i ka helu 80 a 160 (no Tresiba ® FlexTouch ® 100 IU / ml a me Tresiba ® FlexTouch ® 200 IU / ml, pū kekahi), ʻo ia ka liʻiliʻi o 80 a 160 IU o ka insulin i ka peni mau māka (no ka lāʻau lapaʻau Tresiba ® FlexTouch ® 100 PIECES / ml a me Tresiba ® FlexTouch ® 200 PIECES / ml, kekona). Inā hōʻike ka pākōkē helu ma lalo o 80 a 160 (no Tresiba ® FlexTouch ® 100 PIECES / ml a me Tresiba ® FlexTouch ® 200 PIECES / ml, kēlā me kēia), ʻo ia ka mea kūpono o ka nui o nā hui o ka insulin e hōʻike ʻia ma ke counter e waiho ana ma nā penikala syringe. dosis.

E kāʻei i ka mea koho ma ke ʻano ke kūlohelohe a ʻike ʻia nā huahelu “0”.

Inā ʻaʻole lawa ka nui o ka insulin i ka penikala ʻiwikō ʻo ia e lawa i ka dosis piha, hiki iā ʻoe ke komo i ka ʻai i koi ʻia i nā inikua ʻelua e hoʻohana ai i ʻelua peni syringe.

Nā ʻike nui. Pono e mālama pono i ka wā e helu ana i ke koena o ka nui o ka inea o ka insulin.

Inā kānalua ka mea maʻi, ʻoi aku ka maikaʻi e kuhi iā ʻoe iho i ka piha piha o ka insulin e hoʻohana ana i kahi penikala syringe hou. Inā hewahewa ka mea maʻi i kāna mau helu helu, hiki iā ia ke hoʻolauna i kahi kīʻaha ʻaʻole lawa a i ʻole kekahi nui loa o ka insulin, hiki iā ia ke alakaʻi i ka ʻike ʻana o ka pīpī o ke koko e lilo ai i kiʻekiʻe a haʻahaʻa paha.

Pono ʻoe e lawe mau i ka peni syringe me ʻoe.

Pono ʻoe e halihali i kahi peni leka uila a me nā pulelele hou inā neʻe a poino paha lākou.

E mālama i ka peni syringe a me nā pono ma waho o ka hiki ʻana o nā mea a pau, keu nā keiki.

Mai hoʻokaʻawale aku i nā peni ʻula a ka mea maʻi i ka poʻe ʻē aʻe. Hiki i kēia ke alakaʻi i ke kuʻi.

Mai hoʻokaʻawale aku i nā peni ʻula a ka mea maʻi i ka poʻe ʻē aʻe. Hiki i ka lāʻau lapaʻau ke hōʻeha i ko lākou olakino.

Pono nā kahu mālama e hoʻohana pono i nā pono i hoʻohana ʻia me ka mālama nui loa e hōʻemi i ka hopena o ka lāʻau huila a me ke kuʻi ʻana.

Ka mālama peni penu

Pono e mālama ʻia me ka peni syringe. Hiki i ka hana pono ʻole a kūpono ʻole paha ke hopena i ka hala ʻole, hiki iā ia ke alakaʻi i nā kaila kiʻekiʻe ʻole a kiʻekiʻe paha.

Mai haʻalele i ka peni i loko o ke kaʻa a i kahi mau wahi ʻē aʻe ia e ʻikea ai nā pākeke nui loa a i ʻole ka haʻahaʻa.

Mālama i ka peni syringe mai ka lepo, ka lepo a me nā ʻano waiʻai he nui.

Mai holoi i ka peni, mai hoʻomoʻi i ka wai me ka hoʻokahe ʻana iā ia. Inā pono, hiki ke hoʻomaʻemaʻe ʻia ka penikala syringe me ka lole ʻōpala i uhi ʻia me ka papa ʻaʻala.

Mai haʻalele a pākuʻi paha i ka peni ma luna o ka paʻakikī. Inā ua hoʻokuʻu aku ka mea maʻi i ka syringe pen a i kānalua paha ke hana pono nei, e hoʻopili i ka pūwā hou a nānā aku i ka lako o ka insulin i mua o ka hāʻawi ʻana i ka ʻōlelo.

Mai hoʻāʻo e hoʻoponopono hou i ka peni ʻiweluʻe. Pono e hoʻokaʻawale ʻia kahi peni ʻoheʻe.

Mai hoʻāʻo e hoʻoponopono hou i ka peni ʻo ka syringe iā ʻoe iho a lawe ʻē aʻe.